Prab at 20:53, 16 March 2025

2025-03-16T20:53:25Z

← Older revision		Revision as of 20:53, 16 March 2025
Line 31:		Line 31:
	[[Category:Pharmacology]]		[[Category:Pharmacology]]
	[[Category:Thromboembolic disorders]]		[[Category:Thromboembolic disorders]]
	~~{{No image}}~~
	<gallery>		<gallery>
	File:Ethyl_Biscoumacetate.svg\|Ethyl Biscoumacetate		File:Ethyl_Biscoumacetate.svg\|Ethyl Biscoumacetate
	</gallery>		</gallery>

Prab: CSV import

2025-02-25T20:53:44Z

CSV import

← Older revision		Revision as of 20:53, 25 February 2025
Line 32:		Line 32:
	[[Category:Thromboembolic disorders]]		[[Category:Thromboembolic disorders]]
	{{No image}}		{{No image}}
			<gallery>
			File:Ethyl_Biscoumacetate.svg\|Ethyl Biscoumacetate
			</gallery>

Prab: CSV import

2025-02-10T16:57:30Z

CSV import

← Older revision		Revision as of 16:57, 10 February 2025
Line 31:		Line 31:
	[[Category:Pharmacology]]		[[Category:Pharmacology]]
	[[Category:Thromboembolic disorders]]		[[Category:Thromboembolic disorders]]
			{{No image}}

Prab: CSV import

2024-01-22T14:34:09Z

CSV import

New page

== Ethyl biscoumacetate ==

'''Ethyl biscoumacetate''' is a chemical compound that belongs to the class of [[coumarin]] derivatives. It is commonly used as an [[anticoagulant]] medication, primarily for the prevention and treatment of [[thromboembolic disorders]]. Ethyl biscoumacetate is known for its ability to inhibit the synthesis of [[vitamin K-dependent clotting factors]] in the liver, thereby preventing the formation of blood clots.

== Chemical Properties ==

Ethyl biscoumacetate has a molecular formula of C23H28O9 and a molecular weight of 448.47 g/mol. It is a white crystalline powder with a melting point of approximately 160-165°C. The compound is sparingly soluble in water but readily soluble in organic solvents such as ethanol and acetone.

== Pharmacology ==

As an anticoagulant, ethyl biscoumacetate acts by inhibiting the enzyme [[vitamin K epoxide reductase]], which is responsible for the conversion of vitamin K epoxide to its active form. This inhibition disrupts the normal clotting cascade, leading to a decrease in the production of clotting factors II, VII, IX, and X. Consequently, the blood's ability to form clots is reduced, reducing the risk of thromboembolic events.

== Clinical Use ==

Ethyl biscoumacetate is primarily used for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis, pulmonary embolism, and atrial fibrillation. It is often prescribed to patients who are at high risk of developing blood clots, such as those with a history of venous thromboembolism or certain cardiac conditions.

== Side Effects ==

Like any medication, ethyl biscoumacetate can cause side effects. Common side effects include [[nausea]], [[vomiting]], [[diarrhea]], and [[abdominal pain]]. Less frequently, it may cause more serious adverse effects such as [[hemorrhage]] or [[allergic reactions]]. Patients taking ethyl biscoumacetate should be closely monitored for signs of bleeding, and the dosage should be adjusted accordingly.

== Precautions ==

Ethyl biscoumacetate should be used with caution in patients with a history of bleeding disorders, liver disease, or renal impairment. It is contraindicated in individuals with active bleeding, severe hypertension, or hypersensitivity to coumarin derivatives. Additionally, it may interact with other medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and certain antibiotics, so it is important to inform the healthcare provider about all current medications.

== References ==

<references />

[[Category:Anticoagulants]]
[[Category:Coumarin derivatives]]
[[Category:Pharmacology]]
[[Category:Thromboembolic disorders]]

Ethyl biscoumacetate - Revision history

Prab at 20:53, 16 March 2025

Prab: CSV import

Prab: CSV import

Prab: CSV import